LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset
Objective: We aim to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment
Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…Defence Mechanism of Ego and Coping Strategy Style of the Patient with Parkinson’s Disease
Objective: To find out the prevalence of different defence mechanism and coping strategies in the patients with PD.To find out the relationship between using of…Psychosis in Prodromal Parkinson’s disease
Objective: To investigate a possible association between psychosis and prodromal Parkinson’s disease (PD) in a population-based cohort, the Hellenic Longitudinal Investigation of Aging and Diet…Apathy : Clinical Correlates in Parkinson’s disease Psychosis
Objective: To determine the frequency and clinical correlates of apathy in Parkinson’s disease (PD) psychosis. Background: The underlying pathology of apathy in PD psychosis, itself…Clinical Audit of Hospital Admissions for Parkinson Disease
Objective: To review Parkinson patients’ admissions and identify possible preventable admissions so as to develop measures to improve care for Parkinson patients Background: Many studies…Healthcare Resource Utilization and Costs of Parkinson’s Disease Dementia With Psychosis in the US Medicare Population
Objective: To describe healthcare resource use (HCRU) and related costs among Parkinson’s patients with dementia (PDD) and psychosis compared with other dementia types in a…Predictors of Retention for Carbidopa/Levodopa Intestinal Gel in Parkinson Disease
Objective: To identify predictors of discontinuation of levodopa/carbidopa intestinal gel therapy. Background: Although levodopa/carbidopa intestinal gel (LCIG) is an established treatment for Parkinson's disease complicated…Identifying delirium in people with Parkinson’s disease: the Determine-PD pilot study
Objective: To identify the prevalence of delirium in inpatients with Parkinson’s disease (PD). Background: People with PD may be at increased risk of delirium and…Comparison of Dementia Patients With and Without Parkinson’s Disease Before Dementia-related Psychosis Occurs: An Administrative Claims Data Analysis
Objective: Describe and compare patients with evidence of dementia-related psychosis diagnosed with Parkinson’s disease with dementia (PDD) versus patients with dementia but no Parkinson’s disease…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 13
- Next Page »